Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.59 |
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354768 | 0.84 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL25432810 | 0.84 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL30354783 | 0.82 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL25383195 | 0.82 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL30354853 | 0.82 | GAA (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2220506 | 0.82 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL25383306 | 0.81 | MAPK8 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL30354965 | 0.81 | MAPK8 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL8661158 | 0.80 | MAPT (0.58) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL321546 | 0.80 | NOTUM (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177612-A1 | Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2011-07-21 | — | — | US | disclosed |
| US-7829298-B2 | Human G protein-coupled receptors for metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | FFAR1, FFAR2, FFAR3 | NPC1 106/4885RAB9A 2083/4885SMN1; SMN2 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.